We are a Deep Tech 3D Bioprinting Company focussed on the development of products and services for R&D and clinical applications.
We developed our first 3D Bioprinter within the first 7 months, since our inception in May 2016. To create an impact in the domain of 3D Bioprinting, we, at NBIL, developed Trivima, India’s first customisable 3D Bioprinter. The printer has been developed to cater to the diverse requirements of researchers working in the domain of 3D Bioprinting, throughout the world.
With a long term vision to one day bridge the gap between organ demand and availability via 3D Bioengineered organs, our multi-disciplinary team has taken its first step in that direction. We are currently validating our 3D Bioprinted Human Epidermis (Innoskin® HE). Although the initial application for Innoskin® would be in cosmetic, pharmaceutical and chemical testing applications, the long term goal of us, at NBIL, is to translate Innoskin® for a clinical use case.